A Look At West Pharmaceutical Services (WST) Valuation After New Dublin Expansion For Injectable Treatments

West Pharmaceutical Services (WST) has opened a 165,000 square foot expansion at its Damastown, Dublin site, adding advanced automation and commercial scale drug handling to support high volume injectable treatments for diabetes and obesity.

See our latest analysis for West Pharmaceutical Services.

The Dublin expansion has arrived while the share price has been under pressure in recent months, with a 90 day share price return of 7.81% decline but a 1 year total shareholder return of 16.24%, suggesting longer term holders have still seen gains.

If you are looking beyond West and want to see what else is shaping healthcare and drug delivery, this is a good moment to check out 37 healthcare AI stocks.

With West Pharmaceutical Services trading at US$254.80 against an average analyst price target of US$316.69 and carrying a low value score of 1, the key question is whether this recent weakness signals mispricing or if the market is already accounting for future growth.

Most Popular Narrative: 24.7% Undervalued

West Pharmaceutical Services' most followed narrative points to a fair value of $338.57 per share versus the last close of $254.80, putting the recent Dublin expansion into a broader earnings and valuation story anchored on high value drug delivery.

The increase in demand and the transition to higher margin HVP components, supported by approximately 340 Annex 1 projects, is likely to positively impact both revenue and net margins due to a favorable mix shift. The strategic focus on expanding the contract manufacturing business into drug handling, which is expected to be higher margin and require lower capital intensity, could improve net margins and earnings after the initial ramp up phase.

Read the complete narrative.

Want to see what kind of revenue mix and margin profile could justify that higher fair value? The narrative leans heavily on drug delivery volumes, richer components and a premium earnings multiple that assumes investors keep paying up for this type of growth.

Result: Fair Value of $338.57 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors still need to watch for softer revenue assumptions and tariff related cost pressure, either of which could challenge the margin and valuation narrative.

Find out about the key risks to this West Pharmaceutical Services narrative.

Another View On Valuation

The popular fair value of $338.57 suggests West Pharmaceutical Services is undervalued, but the P/E picture tells a different story. The current P/E of 37.2x is higher than the North American Life Sciences industry at 33.8x, the peer average at 30x, and the fair ratio of 20x. This points to valuation risk if sentiment cools.

For an investor, that gap means the market is already paying a premium that could compress if expectations ease. The key question is whether the earnings and margin story stays strong enough to support that higher multiple.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With optimism and risks both in the mix, this is a good time to check the numbers yourself and decide where you stand. To see what the market currently views as the key upsides for this business, review the 2 key rewards

Looking for more investment ideas?

If you stop here, you only see part of the opportunity set. Use the Simply Wall Street Screener to quickly surface fresh ideas that match your style.

• Target potential mispricing across the market by scanning for companies that appear out of favor on price but solid on quality with the 62 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses with stronger financial footing and consistent fundamentals using the solid balance sheet and fundamentals stocks screener (39 results).
• Hunt for future market favorites before they are widely followed by checking the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com